Open AccessEvaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
Author(s) -
Johnson Wallace,
White William B.,
Sica Domenic,
Bakris George L.,
Weber Michael A.,
Handley Alison,
Perez Alfonso,
Cao Charlie,
Kupfer Stuart,
Saunders Elijah B.
Publication year - 2017
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12993
Subject(s) - medicine , placebo , ambulatory blood pressure , confidence interval , ambulatory , blood pressure , adverse effect , clinical endpoint , incidence (geometry) , randomized controlled trial , gastroenterology , pathology , physics , optics , alternative medicine
The efficacy and safety of azilsartan medoxomil ( AZL ‐M) were evaluated in African‐American patients with hypertension in a 6‐week, double‐blind, randomized, placebo‐controlled trial, for which the primary end point was change from baseline in 24‐hour mean systolic blood pressure ( BP ). There were 413 patients, with a mean age of 52 years, 57% women, and baseline 24‐hour BP of 146/91 mm Hg. Treatment differences in 24‐hour systolic BP between AZL ‐M 40 mg and placebo (−5.0 mm Hg; 95% confidence interval, −8.0 to −2.0) and AZL ‐M 80 mg and placebo (−7.8 mm Hg; 95% confidence interval, −10.7 to −4.9) were significant ( P ≤.001 vs placebo for both comparisons). Changes in the clinic BP s were similar to the ambulatory BP results. Incidence rates of adverse events were comparable among the treatment groups, including those of a serious nature. In African‐American patients with hypertension, AZL ‐M significantly reduced ambulatory and clinic BP s in a dose‐dependent manner and was well tolerated.